Keith Loria is a contributing writer to Medical Economics.
ATS Guidelines Highlight Benefits of Pulmonary Rehabilitation
February 7th 2025Patients with chronic obstructive pulmonary disease, interstitial lung disease and pulmonary hypertension experience improved quality of life and functional capacity as measured in the 6-minute walk distance test.
Read More
5 Questions For Respiratory Therapist Educator Brandan Gerry
February 5th 2025The biggest challenge in training the next generation of respiratory therapists is getting them to engage in "critical thinking and getting them to think about the disease process," says educator Brandan Gerry. "Students are good at memorizing tidbits but not always assimilating everything into a clear picture and tying things together."
Read More
Refoxy Pharmaceuticals Secures $9.7 Million to Explore Innovative Treatment for IPF
January 4th 2025Conventional drug development typically zeroes in on individual proteins or signaling pathways. By focusing on the transcription factor FOXO3, Refoxy hopes to harness a key regulator that impacts numerous biological processes.
Read More
Study Highlights Critical Need For Improved Understanding of Childhood Interstitial Lung Disease
December 10th 2024Diagnostic criteria for pulmonary fibrosis and other fibrotic diseases in children are lacking. That void hampers an understanding of how disease progresses in children and adolescents and what the outcomes are.
Read More
Data From Long COVID Study Could Shed Light on Pulmonary Fibrosis Causes and Treatment
November 4th 2024Identifying the underlying causes of prolonged lung inflammation associated with radiographic abnormalities could be key understanding long COVID and other lung conditions, researchers say.
Read More
New Study Points Out Doubling of Hospitalizations and Healthcare Costs for PH-ILD
August 5th 2024A new study conducted by researchers at the United Therapeutics Corporation in Durham, NC, looked to characterize PH-ILD disease burden by analyzing healthcare resource utilization (HCRU) and cost data.
Read More